Haemophilus influenzae b polysaccharide-tetanus conjugate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Haemophilus influenzae b polysaccharide-tetanus conjugate
DrugBank Accession Number
DB15876
Background

Not Available

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Conjugate
Synonyms
  • Haemophilus influenzae b polysaccharide - tetanus conjugate
  • Haemophilus influenzae b polysaccharide-tetanus conjugate
  • Haemophilus influenzae type b polysaccharide conjugated to tetanus protein
  • Haemophilus influenzae type b polysaccharide conjugated to the tetanus protein

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofHaemophilus influenzae type b diseases•••••••••••••••••••••• •••••••••• ••••••• ••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
HEXACIMAHaemophilus influenzae b polysaccharide-tetanus conjugate (29 µg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 µg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 UI) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 UI) + Hepatitis B Vaccine (Recombinant) (10 µg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 U) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 U) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 U)Injection, suspensionIntramuscularSanofi Pasteur2014-07-08Not applicableItaly flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HEXACIMAHaemophilus influenzae b polysaccharide-tetanus conjugate (29 µg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 µg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 UI) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 UI) + Hepatitis B Vaccine (Recombinant) (10 µg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 U) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 U) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 U)Injection, suspensionIntramuscularSanofi Pasteur2014-07-08Not applicableItaly flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for suspensionIntramuscular
Injection, suspensionIntramuscular
Injection, powder, for solutionIntramuscular
Injection, powder, for solutionIntramuscular25 µg
Injection
SuspensionIntramuscular
Injection, powder, for suspensionIntramuscular
Solution / dropsOral
InjectionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at September 23, 2020 16:20 / Updated at September 24, 2020 11:24